Checkpoint-blocking antibodies appear safe, beneficial in elderly melanoma patients

CHICAGO – Programmed cell death protein 1 (PD-1) inhibitors and combination ipilimumab and nivolumab prolonged survival, compared with ipilimumab alone in patients aged 80 and older with advanced melanoma, and the patients experienced no more adverse events than did patients of all age groups in...
Source: Skin and Allergy News - Category: Dermatology Source Type: news